CIAS
LEGN icon

Capital Investment Advisory Services’s Legend Biotech LEGN Stock Holding History

Capital Investment Advisory Services’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-8,525
Closed -$411K – 897
2023
Q1 		$411K Sell
8,525
-2,425
-22% -$119K 0.05% 298
2022
Q4 		$547K Buy
10,950
+500
+5% +$24.2K 0.06% 249
2022
Q3 		$426K Sell
10,450
-700
-6% -$32.9K 0.06% 277
2022
Q2 		$613K Buy
+11,150
New +$471K 0.07% 224

Other funds holding LEGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Capital Investment Advisory Services's LEGN Position: Q2 2023 in Review

Capital Investment Advisory Services sold out of Legend Biotech (LEGN) in Q2 2023, closing a stake of 8,525 shares — an estimated $411K sold.

Capital Investment Advisory Services first reported a position in LEGN in Q2 2022 and held it in 4 quarters. The position peaked at $613K in Q2 2022. 194 funds tracked by Wall St. Rank hold LEGN as of Q2 2023.

  • Capital Investment Advisory Services reported no remaining Legend Biotech position as of Q2 2023 after selling out during the quarter.
  • Capital Investment Advisory Services sold 8,525 Legend Biotech shares in Q2 2023, an estimated $411K.
  • Capital Investment Advisory Services first reported a position in Legend Biotech in Q2 2022 and held it in 4 quarters.
  • Capital Investment Advisory Services's Legend Biotech position peaked at $613K in Q2 2022.
  • 194 funds tracked by Wall St. Rank held Legend Biotech as of Q2 2023.

Based on Capital Investment Advisory Services's 13F filing for Q2 2023, filed 28 Jul 2023.